Premium
Gd‐25 DTPA‐MAb, a potential NMR contrast agent for MRI in the xenografted nude mouse: Preliminary studies
Author(s) -
Curtet Chantal,
Bourgoin Corine,
Bohy Joelle,
Saccavini JeanClaude,
Thédrez Philippe,
Akoka Serge,
Tellier Charles,
Chatal JeanFrançois
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910410728
Subject(s) - monoclonal antibody , gadolinium , chemistry , adenocarcinoma , colon adenocarcinoma , in vivo , in vitro , mri contrast agent , colorectal adenocarcinoma , pathology , contrast (vision) , nude mouse , microbiology and biotechnology , nuclear magnetic resonance , nuclear medicine , antibody , medicine , biology , immunology , biochemistry , cancer , physics , organic chemistry , artificial intelligence , computer science
Abstract Monoclonal antibodies (MAbs) 19‐9 and 73‐3 specific for human colon adenocarcinoma were labelled with a high number of gadolinium atoms. Twenty five DTPA were chelated per MAb, with only slight loss of immunoreactivity. The NMR contrast agent Gd‐25 DTPA‐MAb 19‐9 or 73‐3 ([Gd] 17 μmole/kg, [MAb] 60 μm) was injected into nude mice bearing human colon adenocarcinoma (SW948). Tumours were removed 24 hr after injection and T 1 , was measured in vitro. T 1 relaxation time varied according to MAb specificity against tumour targets; T 1 , decreased 20% for MAb 19‐9 and MAb 73‐3 with SW948 tumour. Imaging was performed with this model. Very good contrast was obtained 24 hr after Gd‐25 DTPA‐MAb injection.